Online ISSN: 2515-8260

Keywords : In summary


Optical and Electronic Structure of a Double Perovskite Oxides Ca2MnCoO6

Ajay Kumar; Sujit Kumar; P. Poddar

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 7834-7841

The prime objective of the present work is evaluating the performance of double Perovskite material with Calcium in the A-site cation and Manganese and Cobalt in the B-site cation. The Ca2MnCoO6 the double Perovskite which is a compound of Calcium, Manganese with cobalt is made in the form of polycrystalline using the attached quartz pipe system. The partial oxygen pressure inside the quartz tube expressed this as an important set parameter for the production of a structural phase model. This parameter was controlled using the ratio between ReO2 and ReO3 content and the filling parameter (ratio between weight and total quartz tab content). Molecular and chemical components were investigated by scanning with electron microscopy and diffraction microscopy. The structural parameters of the crystal were determined by analyzing the X-ray powder distribution pattern with high resolution synchrotron. The analysis indicates that the sample is a single-layer compound compatible with the monolin crystal structure. (Space group P21/n) with a = 5.3649 (2) Å; b = 5.49863 (3) Å; c = 7.77524(3) Å; and β = 90.19(1)º. Computer simulations were performed considering two cation valence settings, that is, (i) Mn2+Re6+ or (ii) Mn3+Re5+, for the Ca2MnCoO6 compound. XANES analysis measurements indicated +2.4 for the means valence of Mn (a mixture of Mn2+ and Mn3+) and +5.8 for the effective valence of Re (an intermediate valence between Re4+ (ReO2) and Re6+ (ReO3)).

Alphavirus E1 Glycoprotein-Liposome-Nucleic Acid Complexes Protect Mice from Lethal Challenge with Multiple Alphaviruses

Rico A; Phillips A; Schountz T; Toth A; Jarvis D; Powers A; Olson K

European Journal of Molecular & Clinical Medicine, 2015, Volume 2, Issue 4, Pages 130-131

Alphaviruses are globally distributed, mosquito borne pathogens that cause death and disease in vertebrates, including humans. Therapeutics to combat alphaviral disease are non-existant and only a handful of IND status vaccines are available. Of the available vaccines most are associated with a poor immunological response and a high rate of reactivity, and none protects against more than a single alphavirus species. We designed and tested novel alphavirus vaccines comprised of the E1 glycoproteins of western equine encephalitis virus (WEEV) or Venezuelan equine encephalitis virus (VEEV). Immunization with cationic lipid nucleic acid complexes (CLNCs) and alphavirus E1ecto mixture (lipid-antigen-nucleic acid complexes:LANACs) provided significant protection in mice challenged with either WEEV, VEEV or eastern equine encephalitis virus (EEEV) regardless of challenge route. LANAC immunized mice mount a strong humoral immune response lacking neutralizing antibody. Passive transfer of immune sera from LANAC immunized mice to non-immunized mice confers protection to challenge, indicating that non-neutralizing antibody is sufficient for protection.